

**MANIPAL UNIVERSITY****M. PHARM. PART-I DEGREE EXAMINATION – MAY/JUNE 2013****SUBJECT: MICROBIAL BIOCHEMISTRY AND IMMUNOLOGY (PBT 601)**  
**(SPECIALIZATION: PHARMACEUTICAL BIOTECHNOLOGY)**

Monday, May 27, 2013

Time: 10:00 – 13:00 Hrs.

Max. Marks: 100

✍ **Answer ALL the questions.**

- 1A. Enlist and classify the various counting techniques used to estimate the bacterial count. Elaborate on the statistical approach.
- 1B. With the help of a neat labelled diagram, explain the lysogenic cycle in bacteriophages. Add a note on its significance.
- (10+10 = 20 marks)
- 2A. Sketch the *De novo* pathway for the synthesis of pyrimidine ribonucleotides. Add a note on contributors of each atom of the pyrimidine ring.
- 2B. Define  $\beta$ -oxidation. Explain in detail  $\beta$ -oxidation of palmitic acid with a note on its energetics.
- (10+10 = 20 marks)
- 3A. With a neat labelled diagram, describe the structure of an antibody.
- 3B. What is TCR-CD3 complex? Emphasize the role of co-receptors in TCR binding affinity.
- (10+10 = 20 marks)
- 4A. What is cancer immunotherapy? Explain the different ways of enhancing immunity against cancer.
- 4B. Explain in detail the principle and instrumentation of immunoblotting. Add a note on its applications.
- (10+10 = 20 marks)
- 5A. Briefly explain electron transport chain and oxidative phosphorylation.
- 5B. Innate immunity collaborates with adaptive immunity to protect the host. Brief on this naming key points of interactions.
- 5C. Briefly explain the role of complement system in immunity.
- 5D. Enlist the different hypersensitive reactions and explain any one.
- (5+5+5+5 = 20 marks)



## MANIPAL UNIVERSITY

M. PHARM. PART-I DEGREE EXAMINATION – MAY/JUNE 2013

SUBJECT: BIOPROCESS ENGINEERING AND TECHNOLOGY (PBT 602)  
(SPECIALIZATION: PHARMACEUTICAL BIOTECHNOLOGY)

Wednesday, May 29, 2013

Time: 10:00 – 13:00 Hrs.

Max. Marks: 100

✍ Answer all the questions. Draw neat labeled diagram wherever necessary.

- 1A. Discuss the basic functions of a fermenter and identify the most critical functions.
- 1B. In establishing continuous culture under steady state conditions, specific growth rate,  $\mu$  equals to dilution rate,  $D$ . Prove it. Compare batch culture with continuous culture for biomass productivity.  
(10+10 = 20 marks)
- 2A. Enlist the mechanisms of filtration. Discuss the Humphrey-Gaden approach of depth filtration.
- 2B. Explain the Scale down approach to overcome the difficulties of Scale-up.  
(10+10 = 20 marks)
- 3A. What is counter-current extraction? Describe the construction and working of Podbielniak extractor.
- 3B. Differentiate precipitation process from crystallization and explain Mier's supersaturation theory.  
(10+10 = 20 marks)
- 4A. Why are homofermentative microorganisms preferred to heterofermentative organisms for production of Lactic acid? Explain the recovery process of Lactic acid from fermented broth.
- 4B. Explain the production of Streptomycin.  
(10+10 = 20 marks)
5. Write short notes on the following:
- 5A. Purpose and types of valves and selection criteria
- 5B. Waldhof type fermenter
- 5C. Various strain improvement techniques and role of recombinant DNA technology
- 5D. Criteria of production medium in industrial fermentations  
(5×4 = 20 marks)



## MANIPAL UNIVERSITY

## M. PHARM. PART-I DEGREE EXAMINATION – MAY/JUNE 2013

SUBJECT: MODERN PHARMACEUTICAL BIOTECHNOLOGY (PBT 603)  
(SPECIALIZATION: PHARMACEUTICAL BIOTECHNOLOGY)

Friday, May 31, 2013

Time: 10:00 – 13:00 Hrs.

Max. Marks: 100

✍ Answer ALL questions.

- 1A. Define recombinant DNA technology and enlist the major steps involved. Explain in detail the role of bacteriophages, YAC and BAC vectors in rDNA technology.
- 1B. Discuss the production of recombinant insulin with critical comments on pro insulin and colony selection.

(10+10 = 20 marks)

- 2A. Discuss the vaccine design strategies in relation to immune response.
- 2B. Discuss the development of genetically modified live vaccines for Bacillus anthracis infection.

(10+10 = 20 marks)

- 3A. Define microarray technology. Explain the different probe-target hybridization and detection techniques.
- 3B. Define Pharmacogenomics and Pharmacogenetics. Explain drug polymorphisms with emphasis on Drug Metabolising Enzymes (DME) and Single nucleotide polymorphism (SNP).

(10+10 = 20 marks)

- 4A. Explain in detail induced pluripotent stem cells and their applications.
- 4B. Enlist different materials used for the manufacture of microfluidic components and explain any two. Add a note on the advantages of microfluidic devices.

(10+10 = 20 marks)

- 5A. What are the advantages of microorganisms over plants and animals for the production of enzymes? Explain in detail the various parameters involved in the selection of enzyme source.
- 5B. Write a short note on therapeutic applications of enzymes.
- 5C. Discuss Algorithms and Data Mining Tools.

(10+5+5 = 20 marks)



## MANIPAL UNIVERSITY

## M. PHARM. PART-I DEGREE EXAMINATION – MAY/JUNE 2013

SUBJECT: MOLECULAR BIOLOGY AND DRUG DISCOVERY (PBT 604)  
(SPECIALIZATION: PHARMACEUTICAL BIOTECHNOLOGY)

Monday, June 03, 2013

Time: 10:00 – 13:00 Hrs.

Max. Marks: 100

✍ Answer ALL the questions.

- 1A. Explain the role of RNA polymerase in transcription with a note on pribnow box, downstream bases and -35 sequences.
- 1B. Enlist different types of gene regulation. Explain *Lac* operon model .  
(10+10 = 20 marks)
- 2A. Explain the general process of cell signaling; add a note with suitable examples on various messengers taking part in signaling.
- 2B. How does an oncogene differ from a tumour suppressor gene? With suitable examples, explain how they can lead to development of cancer.  
(10+10 = 20 marks)
- 3A. With the advancement of molecular biology, the approach for discovery of drugs, especially biopharmaceuticals, has taken new strides. Discuss with special emphasis on genomics.
- 3B. *In-silico* approach for drug design, preceding drug discovery, would lessen the efforts in wet lab. Explain. Oral delivery of biopharmaceuticals, though the most preferred route is problematic. Why?  
(10+10 = 20 marks)
- 4A. Enumerate various sources of biopharmaceuticals and discuss the advantages and limitations of *E. coli* as a source of recombinant therapeutic proteins.
- 4B. Define cytokines and give an account of generalizations with regard to cytokines.  
(10+10 = 20 marks)
- 5A. Write a short note on histones.
- 5B. Mention the various phases in a normal mammalian cell cycle, emphasizing on biochemical changes during various phases with the aid of suitable illustrations.
- 5C. How does MPF regulate early mitotic events such as chromatin condensation and breakdown of nuclear envelope?
- 5D. Define gene therapy and discuss germ line therapy.  
(5+5+5+5 = 20 marks)

